Differential effects of chronic immunosuppression on behavioral, epigenetic, and Alzheimer's disease-associated markers in 3xTg-AD mice
BACKGROUND: Circulating autoantibodies and sex-dependent discrepancy in prevalence are unexplained phenomena of Alzheimer's disease (AD). Using the 3xTg-AD mouse model, we reported that adult males show early manifestations of systemic autoimmunity, increased emotional reactivity, enhanced expression of the histone variant macroH2A1 in the cerebral cortex, and loss of plaque/tangle pathology. Conversely, adult females display less severe autoimmunity and retain their AD-like phenotype. This study examines the link between immunity and other traits of the current 3xTg-AD model.
METHODS: Young 3xTg-AD and wild-type mice drank a sucrose-laced 0.4 mg/ml solution of the immunosuppressant cyclophosphamide on weekends for 5 months. After behavioral phenotyping at 2 and 6 months of age, we assessed organ mass, serologic markers of autoimmunity, molecular markers of early AD pathology, and expression of genes associated with neurodegeneration.
RESULTS: Chronic immunosuppression prevented hematocrit drop and reduced soluble Aβ in 3xTg-AD males while normalizing the expression of histone variant macroH2A1 in 3xTg-AD females. This treatment also reduced hepatosplenomegaly, lowered autoantibody levels, and increased the effector T cell population while decreasing the proportion of regulatory T cells in both sexes. Exposure to cyclophosphamide, however, neither prevented reduced brain mass and BDNF expression nor normalized increased tau and anxiety-related behaviors.
CONCLUSION: The results suggest that systemic autoimmunity increases soluble Aβ production and affects transcriptional regulation of macroH2A1 in a sex-related manner. Despite the complexity of multisystem interactions, 3xTg-AD mice can be a useful in vivo model for exploring the regulatory role of autoimmunity in the etiology of AD-like neurodegenerative disorders.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Alzheimer's research & therapy - 13(2021), 1 vom: 20. Jan., Seite 30 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kapadia, Minesh [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 24.06.2021 Date Revised 04.12.2021 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s13195-020-00745-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320350517 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320350517 | ||
| 003 | DE-627 | ||
| 005 | 20231225173404.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13195-020-00745-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1067.xml |
| 035 | |a (DE-627)NLM320350517 | ||
| 035 | |a (NLM)33472690 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kapadia, Minesh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Differential effects of chronic immunosuppression on behavioral, epigenetic, and Alzheimer's disease-associated markers in 3xTg-AD mice |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.06.2021 | ||
| 500 | |a Date Revised 04.12.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Circulating autoantibodies and sex-dependent discrepancy in prevalence are unexplained phenomena of Alzheimer's disease (AD). Using the 3xTg-AD mouse model, we reported that adult males show early manifestations of systemic autoimmunity, increased emotional reactivity, enhanced expression of the histone variant macroH2A1 in the cerebral cortex, and loss of plaque/tangle pathology. Conversely, adult females display less severe autoimmunity and retain their AD-like phenotype. This study examines the link between immunity and other traits of the current 3xTg-AD model | ||
| 520 | |a METHODS: Young 3xTg-AD and wild-type mice drank a sucrose-laced 0.4 mg/ml solution of the immunosuppressant cyclophosphamide on weekends for 5 months. After behavioral phenotyping at 2 and 6 months of age, we assessed organ mass, serologic markers of autoimmunity, molecular markers of early AD pathology, and expression of genes associated with neurodegeneration | ||
| 520 | |a RESULTS: Chronic immunosuppression prevented hematocrit drop and reduced soluble Aβ in 3xTg-AD males while normalizing the expression of histone variant macroH2A1 in 3xTg-AD females. This treatment also reduced hepatosplenomegaly, lowered autoantibody levels, and increased the effector T cell population while decreasing the proportion of regulatory T cells in both sexes. Exposure to cyclophosphamide, however, neither prevented reduced brain mass and BDNF expression nor normalized increased tau and anxiety-related behaviors | ||
| 520 | |a CONCLUSION: The results suggest that systemic autoimmunity increases soluble Aβ production and affects transcriptional regulation of macroH2A1 in a sex-related manner. Despite the complexity of multisystem interactions, 3xTg-AD mice can be a useful in vivo model for exploring the regulatory role of autoimmunity in the etiology of AD-like neurodegenerative disorders | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a 3xTg-AD mice | |
| 650 | 4 | |a Alzheimer’s disease | |
| 650 | 4 | |a Amyloid-beta | |
| 650 | 4 | |a Autoantibodies | |
| 650 | 4 | |a Autoimmunity | |
| 650 | 4 | |a BDNF | |
| 650 | 4 | |a Cyclophosphamide | |
| 650 | 4 | |a Histone variants | |
| 650 | 4 | |a Sex | |
| 650 | 4 | |a T lymphocytes | |
| 650 | 4 | |a Tau | |
| 650 | 7 | |a Amyloid beta-Peptides |2 NLM | |
| 650 | 7 | |a Amyloid beta-Protein Precursor |2 NLM | |
| 650 | 7 | |a tau Proteins |2 NLM | |
| 700 | 1 | |a Mian, M Firoz |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Donglai |e verfasserin |4 aut | |
| 700 | 1 | |a Hutton, Craig P |e verfasserin |4 aut | |
| 700 | 1 | |a Azam, Amber |e verfasserin |4 aut | |
| 700 | 1 | |a Narkaj, Klotilda |e verfasserin |4 aut | |
| 700 | 1 | |a Cao, Chuanhai |e verfasserin |4 aut | |
| 700 | 1 | |a Brown, Breanna |e verfasserin |4 aut | |
| 700 | 1 | |a Michalski, Bernadeta |e verfasserin |4 aut | |
| 700 | 1 | |a Morgan, David |e verfasserin |4 aut | |
| 700 | 1 | |a Forsythe, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Zovkic, Iva B |e verfasserin |4 aut | |
| 700 | 1 | |a Fahnestock, Margaret |e verfasserin |4 aut | |
| 700 | 1 | |a Sakic, Boris |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Alzheimer's research & therapy |d 2009 |g 13(2021), 1 vom: 20. Jan., Seite 30 |w (DE-627)NLM190604069 |x 1758-9193 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2021 |g number:1 |g day:20 |g month:01 |g pages:30 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s13195-020-00745-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2021 |e 1 |b 20 |c 01 |h 30 | ||